AUS
NZ
UK
CA
USA
IND
Highlights
- Strategic Acquisition: Rhythm Biosciences has entered into an Asset Sale Agreement (ASA) with the administrators of Genetic Technologies Ltd (GTG) to acquire the Genetype business, a leader in genetic risk assessment for cancers.
- Transaction Value: Rhythm will pay AU$0.625 million for the acquisition, funded from existing cash reserves and R&D Tax Incentive payments.
- Business Synergy: The acquisition enhances Rhythm’s capabilities, combining genomic and proteomic technologies to create a powerful platform for early cancer detection.
Rhythm Biosciences Ltd (ASX:RHY), a company focused on advancing cancer diagnostics, has announced its acquisition of the Genetype business from Genetic Technologies Ltd (GTG), which is currently under administration. The acquisition, formalized through a binding Asset Sale Agreement (ASA), represents a significant step in Rhythm’s strategy to accelerate its core business of early cancer detection. This move will expand Rhythm’s portfolio of clinical products and services while driving future growth through synergies with the Genetype business.
Transaction Overview
Rhythm has agreed to a cash purchase of AU$0.625 million for the Genetype assets. The acquisition price includes payments to select trade creditors and assumes responsibility for employee entitlements for the transferring employees in Australia. The transaction is set to complete on 23 December 2024, subject to meeting certain conditions, including the release of securities on the Genetype assets and the acceptance of employment offers by Genetype’s employees. The acquisition will be funded from Rhythm’s existing cash reserves, including proceeds from previous Research and Development Tax Incentive refunds.
Strategic Fit and Synergies
The acquisition of Genetype aligns perfectly with Rhythm’s strategic vision of enhancing its capabilities in the early detection of cancer through both internal development and strategic partnerships. Genetype is a global leader in genetic-integrated risk assessment, offering predictive risk testing for multiple cancers and other significant diseases. This technology, which combines polygenic risk scores with clinical factors, is a key enabler for Rhythm's goal of personalizing cancer detection at an early stage.
The merger of Rhythm’s blood-based clinical diagnostic products with Genetype’s genomic capabilities creates a complementary, robust platform for delivering personalized disease risk assessments. The combination of these two technologies – proteomic and genomic – positions Rhythm as a powerful player in the rapidly expanding field of early cancer detection.
Revenue and Growth Opportunities
The acquisition provides immediate commercial opportunities for Rhythm. Genetype’s recent introduction of a multi-disease product line opens a modest revenue stream that will accelerate returns for Rhythm’s shareholders. Additionally, the established customer base and industry relationships of Genetype offer a valuable opportunity to fast-track the development and market entry of Rhythm’s flagship product, ColoSTAT®.
By integrating the Genetype business, Rhythm not only diversifies its product offerings but also gains access to a more mature, commercialized product platform. This move strengthens Rhythm’s position in both the Australian and U.S. markets and introduces new expertise and resources to the company, further enhancing its development potential.
Expansion and Integration Plans
Rhythm aims to leverage the assets from Genetype to create a scalable and efficient commercial operation. The combination of the two companies will expand their geographical footprint, optimize resource utilization, and drive accelerated growth. Post-acquisition, Rhythm will collaborate with GTG Administrators to ensure a smooth integration of the Genetype business, including transitional support services, to maximize the value of the combined platform.
Funds from Rhythm’s recent R&D Tax Incentive refund, along with its general working capital, will be allocated to the Genetype business to ensure it reaches its full commercial potential.
